drugset
drugset / Trial / NCT00012376

Chemotherapy Plus Sargramostim in Treating Patients With Refractory Myeloid Cancer

NCT00012376 ↗

Phase 1 Completed 35 enrolled National Cancer Institute (NCI)
NaSingle-groupOpen-labelTreatment

Summary

Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Colony-stimulating factors such as sargramostim may increase the number of immune cells found in bone marrow or peripheral blood and may help a person's immune system recover from the side effects of chemotherapy. Phase I trial to study the effectiveness of bryostatin 1 combined with sargramostim in treating patients who have refractory myeloid cancer

Timeline

Start
2001-03
Primary completion
2010-01
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject bryostatin 1 Small molecule — Intravenous
Background sargramostim Protein / enzyme biologic — Subcutaneous

Indications

acute myeloid leukemia with 11q23 abnormalities acute myeloid leukemia with t(8;21)(q22;q22) translocation acute myeloid leukemia, del(5q31-q32) acute myeloid leukemia, inv(16)(p13.1;q22) acute myeloid leukemia, t(16;16)(p13.1;q22) blast phase chronic myelogenous leukemia, BCR-ABL1 positive chronic myelomonocytic leukemia leukemia, myeloid, accelerated-phase myelodysplastic syndrome with ring sideroblasts paroxysmal nocturnal hemoglobinuria thrombocytopenia